Compare CLB & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLB | SGHT |
|---|---|---|
| Founded | 1936 | 2011 |
| Country | United States | United States |
| Employees | 3300 | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.0M | 489.7M |
| IPO Year | 2023 | 2021 |
| Metric | CLB | SGHT |
|---|---|---|
| Price | $10.01 | $8.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $15.00 | $10.17 |
| AVG Volume (30 Days) | ★ 630.2K | 337.0K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $526,520,000.00 | $77,363,000.00 |
| Revenue This Year | N/A | $16.75 |
| Revenue Next Year | $2.52 | $11.78 |
| P/E Ratio | $88.91 | ★ N/A |
| Revenue Growth | ★ 0.51 | N/A |
| 52 Week Low | $9.48 | $3.38 |
| 52 Week High | $20.36 | $9.71 |
| Indicator | CLB | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 47.74 |
| Support Level | $9.72 | $7.77 |
| Resistance Level | $10.74 | $8.82 |
| Average True Range (ATR) | 0.34 | 0.50 |
| MACD | 0.04 | -0.09 |
| Stochastic Oscillator | 40.48 | 27.77 |
Core Laboratories Inc is a providers of proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry, through client relationships. The company operates its business in two segments; Reservoir Description, and Production Enhancement. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services. The company generates majority of its revenue from Reservoir Description segment.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.